John Klich

Title: Innovations in Antibody Biopharmaceuticals by John Klich

Introduction

John Klich is an accomplished inventor based in Freehold, NJ (US). He has made significant contributions to the field of biopharmaceuticals, particularly in the development of antibody formulations. With a total of 2 patents to his name, Klich's work focuses on enhancing the stability and efficacy of antibody-based therapies.

Latest Patents

Klich's latest patents revolve around antibody biopharmaceutical formulations that utilize polymer excipients. His innovative approach involves the use of polyacrylamide-based copolymers, which serve as stabilizing excipients in these formulations. These copolymers do not interact directly with the antibodies or alter their pharmacokinetic properties. By preventing the adsorption of antibodies to the interfaces of the composition, Klich's formulations help avoid undesirable aggregation events and maintain the binding activity of the antibodies. This advancement is crucial for the effective administration of antibody compositions to subjects.

Career Highlights

John Klich is affiliated with Leland Stanford Junior University, where he continues to push the boundaries of biopharmaceutical research. His work has garnered attention for its potential to improve the stability of high-concentration antibody compositions, which is vital for therapeutic applications.

Collaborations

Klich has collaborated with notable colleagues in his field, including Joseph L Mann and Catherine M Kasse. These partnerships have contributed to the advancement of his research and the development of innovative solutions in biopharmaceutical formulations.

Conclusion

John Klich's contributions to the field of antibody biopharmaceuticals highlight the importance of innovation in medical research. His patents reflect a commitment to improving therapeutic efficacy and patient outcomes through advanced formulations.